Article

Hypothyroidism

Dr. Jay Cohen, an endocrinologist, discusses thyroid disease. He reviews the difference between hypo and hyper thyroidism, as well as the treatment of hypothryoidism. Memphis, Tenn. Call 901-763-3636 for more information.

Dr. Jay Cohen, an endocrinologist, discusses thyroid disease. He reviews the difference between hypo and hyper thyroidism, as well as the treatment of hypothryoidism. Memphis, Tenn. Call 901-763-3636 for more information.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Related Content
Jörn M. Schattenberg, MD | Credit: LinkedIn
December 15th 2024

Study Highlights Real-World Mortality Rates, Factors Increasing Mortality Risk in MASH

Patrick Campbell
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia | Image Credit: US Food and Drug Administration
Published: December 13th 2024 | Updated: December 13th 2024

FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia

Connor Iapoce
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
2024 State of Lung Cancer: The Hopes and Hurdles of Precision Oncology with Jacob Sands, MD
December 9th 2024

2024 State of Lung Cancer: The Hopes and Hurdles of Precision Oncology with Jacob Sands, MD

Tim Smith
A Pillared Approach: A Suite of THerapies for a Spectrum of Metabolic Disease
December 6th 2024

A Pillared Approach: A Suite of Therapies for a Spectrum of Metabolic Disease

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.